Millie
your market intelligence analyst
Search Results
480 results
Your search is now limited to «Drugs» expert search.
Users of TRT had a 21 per cent greater risk of cardiovascular events compared with non-users, particularly ischaemic stroke, transient ischaemic attack (TIA), or myocardial infarction.
More from Mail on Sunday (United Kingdom):
ENDPOINTS 07/19/2019 09:48
MyoKardia’s lead drug, mavacamten, is expected to break new ground in heart disease, a field monopolized by large pharmaceutical companies largely due to the long, arduous and expensive trials that are commonplace in heart drug development.
More from ENDPOINTS:
pharmaphorum 07/19/2019 07:40
Yale, Mayo and FDA experts aim to rethink heart failure trials with Apple Watch.
More from pharmaphorum:
Medindia.com 07/19/2019 06:30
Studies indicate that diabetes appreciably elevates the risk of coronary heart disease (CHD) and stroke, as well as other unrelated conditions such as cancer and dementia, in women compared to men.
More from Medindia.com:
Medical Xpress 07/19/2019 01:36
Previous analyses have shown that diabetes confers a greater excess risk of coronary heart disease (CHD) and stroke, as well as of other non-cardiovascular complications including dementia and cancer, in women compared with men.
More from Medical Xpress:
FeedNavigator (EU) 07/18/2019 06:20
Purpose Recent studies have shown that sodium glucose cotransporter 2 (SGLT2) inhibitors have a favorable effect on cardiovascular events in diabetic patients. However, the underlying mechanism...
More from FeedNavigator (EU):
FoodNavigator-Asia 07/17/2019 20:41
In addition to significantly improving conventional cardiometabolic risk factors, reducing the risk of cardiovascular disease by about a factor of 13, trial participants enjoyed major improvements on a range of risk factors linked to problems such as type 2 diabetes, stroke, inflammation and some forms of cancer.
Becker's Hospital Review 07/17/2019 17:56
Yale University and Rochester, Minn.-based Mayo Clinic are partnering with Bifourmis, a digital therapeutics company, to study the use of patient-measured data to determine effective drug development for heart failure patients.
More from Becker's Hospital Review:
HIT Consultant Media 07/17/2019 15:53
FDA recognizes in its recent draft guidance, Treatment for Heart Failure: Endpoints for Drug Development Guidance for Industry, that an effect on symptoms or physical function, without a favorable effect on survival or risk of hospitalization can be a basis for approving drugs to treat heart ...
More from HIT Consultant Media:
mHealthIntelligence 07/17/2019 14:14
... outcomes such as mortality and hospitalization rates have served as the traditional endpoints in clinical studies, we also should take into consideration the patients' levels of satisfaction and well-being while being treated with a heart failure drug during a trial.
More from mHealthIntelligence:
The ARTEMIS studies evaluated 1,122 subjects on the efficacy and safety of Bimatoprost SR versus timolol, a FDA standard comparator for registrational clinical trials, in patients with open-angle glaucoma or ocular hypertension.
More from Healthcare Sales & Marketing Network:
FierceBiotech 07/16/2019 14:59
The partnership follows the agency's draft guidance on endpoints for the development of heart failure drugs.
More from FierceBiotech:
PR Newswire 07/16/2019 07:55
FDA recognizes in its recent draft guidance, Treatment for Heart Failure: Endpoints for Drug Development Guidance for Industry, that an effect on symptoms or physical function, without a favorable effect on survival or risk of hospitalization, can be a basis for approving drugs to treat heart ...
More from PR Newswire:
Top Class Actions 07/16/2019 07:00
Studies have shown a strong association between Uloric and serious cardiovascular injury, including cardiac arrest (both fatal and non-fatal), stroke and myocardial ischemia, or oxygen deprivation due to reduced blood circulation.
More from Top Class Actions:
ClinicalTrials.gov 07/16/2019 06:52
Condition : Atherosclerotic Heart Disease With Angina Nos Intervention : Drug: Chinese patent medicine Sponsor : Tianjin University of Traditional Chinese Medicine Not yet recruiting.
More from ClinicalTrials.gov:
PharmiWeb.com 07/16/2019 06:28
Global Heart Failure Drugs Market report is first of its kind research report that incorporates the overview, summary, market dynamics, competitive analysis, and leading player’s various strategies to sustain in the worldwide market.
More from PharmiWeb.com:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications